TScan Therapeutics, Inc. TCRX
0.19 USD 0.00 (+1.98%)
At closeNov 10, 2026, 5:17 PM EST
0.19 0.00 +2.59%
After hours · Nov 10, 5:17 PM ET
0.1753 Day range 0.1987
0.171 52-week range 1.47
- YTD
- -81.48%
- 1 year
- -83.01%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 19.3% to $1.14 during Tuesday's after-market session. The company's market cap stands at $1.8 million. Edesa Biotech (NASDAQ:EDSA)…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
defenseworld.net Contrasting TScan Therapeutics (NASDAQ:TCRX) and BioNTech (NASDAQ:BNTX) BioNTech (NASDAQ: BNTX - Get Free Report) and TScan Therapeutics (NASDAQ: TCRX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses…
benzinga.com HC Wainwright & Co. Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1 HC Wainwright & Co. analyst Andres Y. Maldonado downgrades TScan Therapeutics (NASDAQ:TCRX) from Buy to Neutral and lowers the price target from $7 to $1.
benzinga.com Wedbush Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1 Wedbush analyst David Nierengarten downgrades TScan Therapeutics (NASDAQ:TCRX) from Outperform to Neutral and lowers the price target from $5 to $1.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares…
seekingalpha.com TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
benzinga.com Crude Oil Moves Higher; US Factory Orders Rise In July U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.
benzinga.com TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction TScan Therapeutics Inc. (NASDAQ:TCRX) on Wednesday announced a major corporate reorganization to prioritize its in vivo solid tumor pipeline, prompting a workforce reduction of approximately 75%.
benzinga.com TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction The strategic pivot focuses TScan's efforts on developing in vivo-engineered TCR-T therapies.
benzinga.com Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.
globenewswire.com TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market session. The market value of their outstanding shares is at $7.2 million. The company's, Q4 earnings…
benzinga.com Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics; Termination Of Collaboration Agreement Effective November 10, 2026 On August 12, 2026, TScan Therapeutics, Inc. (the "Company") received notice from Amgen Inc. ("Amgen") of its election to terminate, in its entirety, the Research Collaboration and License Agreement,- benzinga.com HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $7 price target.
zacks.com TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.
benzinga.com TScan Therapeutics Q2 EPS $(0.23) Misses $(0.21) Estimate, Sales $1.051M Miss $1.667M Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 17.86 percent increase over losses of…
globenewswire.com TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready…
globenewswire.com TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell…
globenewswire.com TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell…
benzinga.com Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $5 price target.
benzinga.com TScan Says Cancer Therapy Data Support Move to Phase 3 Trial TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients…
globenewswire.com TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation 11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101
gurufocus.com Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology c- benzinga.com TScan Therapeutics Partners With Cellares To Evaluate Automated Clinical Manufacturing Of TSC-101, The Company's Lead TCR-T Therapy Candidate For Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T…
businesswire.com Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies SOUTH SAN FRANCISCO, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a…
benzinga.com Earnings Scheduled For May 6, 2026 
zacks.com TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.26 per share a year ago.
benzinga.com TScan Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate, Sales $982.000K Miss $2.500M Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 15.38 percent increase over losses of…
globenewswire.com TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 ™ ) planned for the second quarter…
globenewswire.com TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
globenewswire.com TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5 Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.
zacks.com TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago.
benzinga.com Earnings Breakdown: TScan Therapeutics Q4 - benzinga.com TScan Therapeutics Q4 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 26.53 percent. This is a 37.93 percent increase over losses of…
globenewswire.com TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Presented positive updated data from the ALLOHA ™ Phase 1 heme trial at 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of…- benzinga.com TScan Therapeutics Completes Enrollment Into Cohort C Of ALLOHA Study Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing processReceived FDA clearance of INDs for TSC-102-A01 and TSC-102-A03…
globenewswire.com TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process
globenewswire.com TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell…
defenseworld.net TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Brokerages TScan Therapeutics, Inc. (NASDAQ: TCRX - Get Free Report) has received an average rating of "Hold" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com TScan Therapeutics Announced Saturday, Updated Data from the ALLOHA Phase 1 Heme Trial; 3/3 Of TSC-101-treated Patients Who Reached Two-year Follow-up Remained Relapse-free Vs. 1/4 In Control Arm TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $7 HC Wainwright & Co. analyst Andres Y. Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $10 to $7.
- benzinga.com TScan Therapeutics Q3 EPS $(0.28) Beats $(0.30) Estimate, Sales $2.511M Beat $1.980M Estimate TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 5.41 percent. This is a 12 percent decrease over losses of…